NO20081365L - Ny krystallinsk form av et pyridazino[4,5-b]indolderivat - Google Patents

Ny krystallinsk form av et pyridazino[4,5-b]indolderivat

Info

Publication number
NO20081365L
NO20081365L NO20081365A NO20081365A NO20081365L NO 20081365 L NO20081365 L NO 20081365L NO 20081365 A NO20081365 A NO 20081365A NO 20081365 A NO20081365 A NO 20081365A NO 20081365 L NO20081365 L NO 20081365L
Authority
NO
Norway
Prior art keywords
pyridazino
crystalline form
new crystalline
indole derivative
indole
Prior art date
Application number
NO20081365A
Other languages
English (en)
Inventor
John D Higgins
William L Rocco
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081365(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of NO20081365L publication Critical patent/NO20081365L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet en ny krystallinsk form av 7-klor-N,N-5-trimetyl-4-okso-3-fenyl-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid, fremgangsmåter for fremstilling av nevnte krystallinske form av 7-klor-N,N-5-trimetyl-4-okso-3-fenyl-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid, preparater omfattende nevnte form i blanding med ett eller flere farmasøytisk akseptable hjelpestoffer og anvendelser av samme.
NO20081365A 2005-08-29 2008-03-14 Ny krystallinsk form av et pyridazino[4,5-b]indolderivat NO20081365L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (en) 2005-08-29 2006-08-24 Novel crystalline form of a pyridazino [4 , 5-b] indole derivative

Publications (1)

Publication Number Publication Date
NO20081365L true NO20081365L (no) 2008-04-03

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081365A NO20081365L (no) 2005-08-29 2008-03-14 Ny krystallinsk form av et pyridazino[4,5-b]indolderivat

Country Status (31)

Country Link
US (1) US7683062B2 (no)
EP (1) EP1924585B1 (no)
JP (1) JP5063600B2 (no)
KR (2) KR20130087059A (no)
CN (1) CN101253176B (no)
AR (1) AR057099A1 (no)
AT (1) ATE531717T1 (no)
AU (1) AU2006285142B2 (no)
BR (1) BRPI0615259A2 (no)
CA (1) CA2619284C (no)
CR (1) CR9723A (no)
CY (1) CY1112317T1 (no)
DK (1) DK1924585T3 (no)
EA (1) EA014164B1 (no)
EC (1) ECSP088209A (no)
ES (1) ES2375841T3 (no)
HR (1) HRP20120073T1 (no)
IL (1) IL189276A (no)
MA (1) MA30000B1 (no)
NO (1) NO20081365L (no)
NZ (1) NZ566087A (no)
PL (1) PL1924585T3 (no)
PT (1) PT1924585E (no)
RS (1) RS52318B (no)
SI (1) SI1924585T1 (no)
TN (1) TNSN08059A1 (no)
TW (1) TW200813060A (no)
UA (1) UA91716C2 (no)
UY (1) UY29771A1 (no)
WO (1) WO2007027525A1 (no)
ZA (1) ZA200801890B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678125C (en) * 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP2008501657A (ja) * 2004-06-02 2008-01-24 サンド・アクチエンゲゼルシヤフト 結晶形態のメロペネム中間体
CN101287706A (zh) * 2005-09-21 2008-10-15 尼科梅德有限责任公司 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
US7728129B2 (en) * 2005-10-31 2010-06-01 Janssen Pharmaceutica Nv Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
RU2011110241A (ru) * 2008-08-18 2012-09-27 САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи (US) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФА 7-ХЛОР-N,N,5-ТРИМЕТИЛ-4-ОКСО-3-ФЕНИЛ-3,5-ДИГИДРО-4Н-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-АЦЕТАМИДА
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2cアゴニストの非吸湿性塩
JP2014530805A (ja) * 2011-09-30 2014-11-20 スンシネ ルアケ プハルマ カンパニー リミテッド アジルサルタンの結晶形並びにその製造及び使用
NZ630803A (en) * 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
WO2005034999A2 (en) 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer

Also Published As

Publication number Publication date
IL189276A0 (en) 2008-08-07
AU2006285142B2 (en) 2012-06-14
CY1112317T1 (el) 2015-12-09
NZ566087A (en) 2011-03-31
TNSN08059A1 (en) 2009-07-14
HK1123794A1 (en) 2009-06-26
UA91716C2 (ru) 2010-08-25
RS52318B (sr) 2012-12-31
JP5063600B2 (ja) 2012-10-31
SI1924585T1 (sl) 2012-09-28
DK1924585T3 (da) 2012-02-27
CA2619284A1 (en) 2007-03-08
EP1924585B1 (en) 2011-11-02
EP1924585A1 (en) 2008-05-28
MA30000B1 (fr) 2008-12-01
BRPI0615259A2 (pt) 2011-05-17
PT1924585E (pt) 2012-01-19
PL1924585T3 (pl) 2012-08-31
IL189276A (en) 2012-07-31
TW200813060A (en) 2008-03-16
EA014164B1 (ru) 2010-10-29
US7683062B2 (en) 2010-03-23
CA2619284C (en) 2014-04-29
HRP20120073T1 (hr) 2012-07-31
ES2375841T3 (es) 2012-03-06
KR20080050577A (ko) 2008-06-09
KR20130087059A (ko) 2013-08-05
CN101253176A (zh) 2008-08-27
WO2007027525A1 (en) 2007-03-08
JP2009506116A (ja) 2009-02-12
EA200800716A1 (ru) 2008-08-29
CR9723A (es) 2008-06-18
ZA200801890B (en) 2009-11-25
AU2006285142A1 (en) 2007-03-08
ATE531717T1 (de) 2011-11-15
ECSP088209A (es) 2008-06-30
AR057099A1 (es) 2007-11-14
CN101253176B (zh) 2012-04-18
US20080139569A1 (en) 2008-06-12
UY29771A1 (es) 2007-03-30

Similar Documents

Publication Publication Date Title
NO20081365L (no) Ny krystallinsk form av et pyridazino[4,5-b]indolderivat
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
UA93043C2 (ru) ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА
NO20052805L (no) Substituerte pyrrolo-pyrazolderivater som kinase-inhibitorer
NO2013017I1 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt, en forløper eller derivat, for eksempel ekstrometorfanhydrobromid og spesielt dekstrometorfanhydrobromid monohydrat; og (b) quinidin eller etfarmasøytisk akseptabelt salt, en forløper eller derivat derav, for eksempel quinidin og spesielt quinidinsulfat dihydrat
WO2002050061A8 (en) Piperazine derivatives for treatment of bacterial infections
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
ECSP055780A (es) Derivados de indol utiles para el tratamiento de enfermedades
NO2012006I1 (no) Telaprevir og enhver terapeutisk ekvivalent form derav som er beskyttet av basispatentet, slik som farmasøytisk akseptable salter og/eller solvater avtelaprevir eller solvater av slike salter
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
NO20044974L (no) Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
CL2008001345A1 (es) Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras.
UA94052C2 (uk) Похідні піридазину
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
NO20043038L (no) Polymorfe former av klopidogrel-hydrogensulfat
DK1737459T3 (da) Imidazopyridin og imidazopyrimidinderivater som antibakterielle midler
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
NO20056178L (no) CCI-779 lyofiliserte formuleringer
NO20080033L (no) Kinolinderivater som NK3-antagonister
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
WO2005105753A3 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
NO20090332L (no) 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler
WO2006052886A8 (en) Metabolites of certain [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application